The global telmisartan market attained a value of USD 3.83 billion in 2022. The market is expected to grow at a CAGR of 3.5% during the forecast period of 2023-2031 to attain a value of USD 5.22 billion by 2031.
Telmisartan is also used to reduce the risk of stroke in patients who cannot take angiotensin-converting enzyme (ACE) inhibitors. Furthermore, it can be used to reduce the risk of death after a heart attack in people who are intolerant to ACE inhibitors.
The most common side effects of telmisartan include sinus pain and congestion, back pain, and diarrhoea. However, more serious side effects, such as kidney problems, high potassium levels, and low blood pressure, can also occur.
It is very important to note that individuals should only take telmisartan under the supervision of a healthcare professional, as adjustments to the dose might be required based on individual circumstances, such as kidney function, other medical conditions, and other medications being taken.
Firstly, the rise in prevalence of hypertension and related cardiovascular conditions around the world is a key driver. Hypertension is often called a 'silent killer' because it frequently goes unnoticed until it causes serious health problems. As awareness about the dangers of untreated hypertension increases, so does the demand for effective medications like telmisartan. In many parts of the world, especially in lower-income countries, the number of people diagnosed with hypertension is rising, increasing the need for cost-effective, accessible treatments.
Secondly, the aging population in many countries is another factor leading to a surge in the market. As people age, the risk of developing hypertension increases, leading to a higher demand for medications such as telmisartan. This is particularly the case in developed nations with large aging populations like the United States, Japan, and many countries in Western Europe.
There's also an increase in demand for generic drugs. Telmisartan has been available as a generic medication for several years, making it a cost-effective alternative to brand-name angiotensin receptor blockers (ARBs). The market for generics is expected to grow, and this will have a positive impact on the telmisartan market as well.
However, the market also faces some challenges. One of these is the side effects associated with telmisartan use, such as kidney problems, high potassium levels, and low blood pressure. These side effects could deter some patients and doctors from choosing this drug. There is also significant competition from other antihypertensive drugs, such as ACE inhibitors, calcium channel blockers, and other ARBs.
Furthermore, the patent expiry of major brands of telmisartan has opened up the market to the production of generic drugs, leading to increased competition and price reductions.
Telmisartan Market: Introduction
Telmisartan is an oral medication that is primarily used to treat high blood pressure (hypertension). It's a type of drug known as an angiotensin II receptor blocker (ARB). This medication works by blocking the action of a substance in the body that causes the blood vessels to constrict. As a result, telmisartan relaxes the blood vessels, which lowers blood pressure and increases the supply of blood and oxygen to the heart.Telmisartan is also used to reduce the risk of stroke in patients who cannot take angiotensin-converting enzyme (ACE) inhibitors. Furthermore, it can be used to reduce the risk of death after a heart attack in people who are intolerant to ACE inhibitors.
The most common side effects of telmisartan include sinus pain and congestion, back pain, and diarrhoea. However, more serious side effects, such as kidney problems, high potassium levels, and low blood pressure, can also occur.
It is very important to note that individuals should only take telmisartan under the supervision of a healthcare professional, as adjustments to the dose might be required based on individual circumstances, such as kidney function, other medical conditions, and other medications being taken.
Telmisartan Market Segmentations
The market can be categorised into strength, indication, distribution channel, and region.Market Breakup by Strength
- 20 mg
- 40 mg
- 80 mg
Market Breakup by Indication
- Hypertension
- Stroke
- Cardiac Arrest
- Others
Market Breakup by Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
Telmisartan Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Telmisartan Market Scenario
The global market for telmisartan has shown promising growth due to a number of factors.Firstly, the rise in prevalence of hypertension and related cardiovascular conditions around the world is a key driver. Hypertension is often called a 'silent killer' because it frequently goes unnoticed until it causes serious health problems. As awareness about the dangers of untreated hypertension increases, so does the demand for effective medications like telmisartan. In many parts of the world, especially in lower-income countries, the number of people diagnosed with hypertension is rising, increasing the need for cost-effective, accessible treatments.
Secondly, the aging population in many countries is another factor leading to a surge in the market. As people age, the risk of developing hypertension increases, leading to a higher demand for medications such as telmisartan. This is particularly the case in developed nations with large aging populations like the United States, Japan, and many countries in Western Europe.
There's also an increase in demand for generic drugs. Telmisartan has been available as a generic medication for several years, making it a cost-effective alternative to brand-name angiotensin receptor blockers (ARBs). The market for generics is expected to grow, and this will have a positive impact on the telmisartan market as well.
However, the market also faces some challenges. One of these is the side effects associated with telmisartan use, such as kidney problems, high potassium levels, and low blood pressure. These side effects could deter some patients and doctors from choosing this drug. There is also significant competition from other antihypertensive drugs, such as ACE inhibitors, calcium channel blockers, and other ARBs.
Furthermore, the patent expiry of major brands of telmisartan has opened up the market to the production of generic drugs, leading to increased competition and price reductions.
Innovation and development of newer drug delivery systems could also influence the market scenario
. Novel formulations that could improve patient compliance, like combination pills (e.g., telmisartan with amlodipine or hydrochlorothiazide), could impact the market positively.Overall, the telmisartan market scenario
will likely continue to be influenced by the dynamics of supply and demand, the evolving healthcare landscape, regulatory changes, and advancements in drug development and delivery technologies.Key Players in the Global Telmisartan Market
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the telmisartan market are as follows:- Novartis AG
- Astellas Pharma Inc
- Nippon Boehringer Ingelheim
- Abbott
- Hema Pharmaceuticals Pvt. Ltd
- Pfizer Inc
- Aurobindo Pharma
- Sun Pharmaceutical Industries Limited
- Glaxosmithkline Plc (GSK)
- Zydus Cadila
Table of Contents
1 Preface2 Report Coverage - Key Segmentation and Scope4 Key Assumptions7 Opportunities and Challenges in the Market16 Key Trends and Developments in the MarketAdditional Customisations Available
3 Report Description
5 Executive Summary
6 Snapshot
8 Global Telmisartan Market Analysis
9 North America Telmisartan Market Analysis
10 Europe Telmisartan Market Analysis
11 Asia Pacific Telmisartan Market Analysis
12 Latin America Telmisartan Market Analysis
13 Middle East and Africa Telmisartan Market Analysis
14 Market Dynamics
15 Competitive Landscape
1 Manufacturing Process
Companies Mentioned
- Novartis AG
- Astellas Pharma Inc.
- Nippon Boehringer Ingelheim
- Abbott
- Hema Pharmaceuticals Pvt. Ltd.
- Pfizer Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | May 2023 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 3.96 Billion |
| Forecasted Market Value ( USD | $ 5.22 Billion |
| Compound Annual Growth Rate | 3.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 6 |
